XML 95 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration] Sales Sales Sales
Cost of sales $ 15,193 $ 16,126 $ 17,411
Selling, general and administrative 10,816 10,504 10,042
Research and development 17,938 30,531 13,548
Other current assets 38,782 32,168  
Accrued and other current liabilities 15,694 15,766  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,481 1,296 1,170
Cost of sales 378 311 492
Selling, general and administrative 165 192 185
Research and development 77 79 106
Other current assets 424 341  
Accrued and other current liabilities 713 256  
Other Noncurrent Liabilities 0 600  
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement 1,311 1,199 1,116
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue from collaborative arrangement $ 170 $ 97 $ 54